Eisai Co., Ltd.'s DAC Research 1. Delivering EBET using the CEACAM6 antibody degrades BRD (bromodomain proteins) in CEACAM6-positive pancreatic cancer cells. 2. They regulate pancreatic cancer stromal signaling through a bystander effect on CEACAM6-negative CAFs (cancer-associated fibroblasts). STAT3, a key signaling molecule in CAFs, is functionally linked to BRD2/4, and EBET payloads diffused from pancreatic cancer cells inhibit STAT3 signaling in CAFs. 3. The #84.7 antibody has a lower binding affinity to normal cells like MPCs (myeloid progenitor cells) than existing CEACAM6 antibodies, reducing side effects on normal cells.
Anti- CEACAM6 antibody+ BET protein degrader conjugate inhibits tumour growth in pancreatic cancer models. https://lnkd.in/g43BaqPm
